Day One Biopharma's OJEMDA received FDA accelerated approval in 2024 for relapsed/refractory BRAF-altered pediatric low-grade glioma, with strong Phase 2 trial results and ongoing Phase 3 studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback